| Primary |
| Glioblastoma Multiforme |
32.4% |
| Glioblastoma |
12.0% |
| Brain Neoplasm |
10.6% |
| Drug Use For Unknown Indication |
9.3% |
| Malignant Melanoma |
5.6% |
| Product Used For Unknown Indication |
5.2% |
| Brain Neoplasm Malignant |
4.4% |
| Metastatic Malignant Melanoma |
3.1% |
| Oligodendroglioma |
2.9% |
| Neoplasm Malignant |
2.3% |
| Glioma |
2.2% |
| Astrocytoma |
1.5% |
| Acute Myeloid Leukaemia |
1.5% |
| Anaplastic Astrocytoma |
1.4% |
| Neuroblastoma |
1.4% |
| Neoplasm |
1.1% |
| Neuroendocrine Carcinoma Metastatic |
0.8% |
| Neuroendocrine Tumour |
0.8% |
| Breast Cancer Metastatic |
0.7% |
| Medulloblastoma Recurrent |
0.7% |
|
| Death |
21.0% |
| Vomiting |
11.4% |
| Thrombocytopenia |
9.8% |
| Pancytopenia |
9.7% |
| Platelet Count Decreased |
7.4% |
| White Blood Cell Count Decreased |
5.8% |
| Disease Progression |
4.1% |
| Pulmonary Embolism |
3.8% |
| Thrombosis |
3.3% |
| Neoplasm Progression |
3.0% |
| Pneumonia |
2.5% |
| Pyrexia |
2.3% |
| Aplastic Anaemia |
2.2% |
| Bone Marrow Failure |
2.0% |
| Deep Vein Thrombosis |
2.0% |
| Rash |
2.0% |
| Sepsis |
2.0% |
| Drug Ineffective |
1.9% |
| Nausea |
1.9% |
| Urinary Tract Infection |
1.9% |
|
| Secondary |
| Glioblastoma Multiforme |
38.5% |
| Drug Use For Unknown Indication |
20.8% |
| Glioblastoma |
13.8% |
| Malignant Melanoma |
4.6% |
| Malignant Glioma |
3.5% |
| Product Used For Unknown Indication |
2.9% |
| Brain Neoplasm |
2.7% |
| Metastatic Malignant Melanoma |
1.8% |
| Nausea |
1.8% |
| Astrocytoma, Low Grade |
1.5% |
| Convulsion |
1.5% |
| Brain Neoplasm Malignant |
1.4% |
| Neoplasm Malignant |
0.9% |
| Neoplasm |
0.8% |
| Anaplastic Astrocytoma |
0.7% |
| Glioma |
0.7% |
| Central Nervous System Lymphoma |
0.6% |
| Oligodendroglioma |
0.6% |
| Brain Oedema |
0.5% |
| Deep Vein Thrombosis |
0.5% |
|
| Vomiting |
14.3% |
| Death |
10.4% |
| White Blood Cell Count Decreased |
8.4% |
| Swelling Face |
7.5% |
| Thrombocytopenia |
7.5% |
| Weight Decreased |
6.8% |
| Pyrexia |
5.2% |
| Syncope |
4.9% |
| Disease Progression |
3.6% |
| Encephalopathy |
3.6% |
| Neutropenia |
3.6% |
| Thrombosis |
3.2% |
| Deep Vein Thrombosis |
2.9% |
| Somnolence |
2.9% |
| Pulmonary Embolism |
2.6% |
| Renal Failure |
2.6% |
| Stevens-johnson Syndrome |
2.6% |
| Unresponsive To Stimuli |
2.6% |
| Visual Disturbance |
2.6% |
| Platelet Count Decreased |
2.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
29.4% |
| Glioblastoma Multiforme |
14.2% |
| Product Used For Unknown Indication |
9.7% |
| Convulsion |
6.0% |
| Brain Neoplasm Malignant |
5.3% |
| Malignant Melanoma |
5.3% |
| Brain Neoplasm |
5.2% |
| Pain |
3.4% |
| Chemotherapy |
2.7% |
| Glioblastoma |
2.7% |
| Deep Vein Thrombosis |
2.4% |
| Nausea |
2.1% |
| Pulmonary Embolism |
2.1% |
| Metastatic Malignant Melanoma |
1.8% |
| Contraception |
1.6% |
| Blood Cholesterol Increased |
1.3% |
| Nuclear Magnetic Resonance Imaging |
1.3% |
| Oligodendroglioma |
1.3% |
| Pneumonia |
1.3% |
| Anaplastic Astrocytoma |
1.0% |
|
| Death |
16.1% |
| Vomiting |
11.3% |
| Disease Progression |
10.5% |
| Visual Impairment |
7.3% |
| Brain Neoplasm |
5.6% |
| Urinary Tract Infection |
5.6% |
| Malignant Neoplasm Progression |
4.0% |
| Metastatic Malignant Melanoma |
4.0% |
| Diarrhoea |
3.2% |
| Haemoglobin Decreased |
3.2% |
| Pain In Extremity |
3.2% |
| Pulmonary Embolism |
3.2% |
| Thrombocytopenia |
3.2% |
| Thrombophlebitis |
3.2% |
| Tremor |
3.2% |
| White Blood Cell Count Decreased |
3.2% |
| Hemiparesis |
2.4% |
| Metastases To Central Nervous System |
2.4% |
| Neoplasm Malignant |
2.4% |
| Neoplasm Progression |
2.4% |
|
| Interacting |
|
| Blood Urine Present |
100.0% |
|
